Mesenchymal Stem Cell Potency Screening Through Protein Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a method to identify and select mesenchymal stem cell populations suitable for therapeutic applications, particularly for wound healing, under Good Manufacturing Practice (GMP) conditions, due to intrinsic variability among donors and tissues, which affects their suitability for clinical use.
Innovation Solution
Determine the secretion levels of Angiopoietin 1 (Ang-1), Transforming Growth Factor beta (TGF-β), Vascular Endothelial Growth Factor (VEGF), and Hepatocyte Growth Factor (HGF) in the medium to assess wound healing potency and select suitable mesenchymal stem cell populations for GMP production, pharmaceutical administration, and generating a master cell bank.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If mesenchymal stem cell populations are selected from various tissues without specific criteria, then the availability and ease of obtaining stem cells is improved, but the consistency and reliability of wound healing potency deteriorates due to intrinsic variability among donors and tissues
Solution Approach 1:
The patent applies parameter changes by establishing specific quantitative thresholds for protein secretion levels (Ang-1, TGF-β, VEGF, HGF) to define suitable mesenchymal stem cell populations. This transforms the selection criterion from qualitative tissue origin to quantitative functional output, ensuring consistent wound healing potency across different tissue sources while maintaining ease of manufacture through standardized assessment protocols
Solution Approach 2:
The patent implements feedback by using protein secretion level measurements to assess and select mesenchymal stem cell populations with optimal wound healing properties. This feedback mechanism allows for quality control and selection of cell populations that meet predetermined potency criteria, ensuring reliability while accommodating various tissue sources
2Reliability
If strict quality control criteria based on protein secretion levels are implemented, then the reliability and consistency of wound healing potency is improved, but the complexity of the assessment process and manufacturing increases
Solution Approach 1:
The patent simplifies the complex assessment process by reducing it to measurement of four key protein secretion parameters (Ang-1, TGF-β, VEGF, HGF) with predetermined thresholds. This transforms a potentially complex multi-parameter assessment into a focused evaluation of critical functional outputs, improving reliability while controlling manufacturing complexity through standardized measurement protocols
Data Source
AI summary
The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.